an open-label randomized controlled trial to compare the immunogenicity and safety of the 2023 southern hemisphere HD QIIV at 60 ug (Effluelda, Sanofi) versus double standard-dose QIIV at 30 ug (Fluarix tetra, Sanofi) in adult kidney transplant (KT) recipients.
Latest Information Update: 26 May 2025
At a glance
- Drugs GSK 2321138A (Primary) ; Influenza virus vaccine (Primary) ; Mycophenolate mofetil; Prednisolone; Tacrolimus
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 26 May 2025 New trial record